查詢結果分析
相關文獻
- 基因工程產製豬白血球中介質Ⅱ對豬隻接種豬生殖與呼吸綜合症死毒免疫效力的影響
- 豬生殖與呼吸綜合症病毒「gp5重組蛋白」的表現與單株抗體之製備
- 年齡、豬生殖與呼吸綜合症病毒及豬霍亂沙氏桿菌感染對豬肺泡巨噬細胞的表現型和功能之影響
- 豬生殖與呼吸綜合症:臺灣分離病毒株感染新生仔豬之致病機制
- Sequence Analysis of Two Membrane-Associated Protein Genes of a Porcine Reproductive and Respiratory Syndrome Virus, Taiwan MD-001 Strain
- 斷奶豬再注射鐵劑和使用血漿蛋白粉末和豬腸水解產物對於生長表現、體液免疫力和氨基酸可消化力之影響研究報導
- PRRS 在日本的現況及控制
- 以反轉錄聚合酶鏈反應鑑定臺灣豬生殖與呼吸綜合症分離病毒株之型別
- 豬生殖與呼吸綜合症減毒疫苗之開發
- 豬隻免疫力和疫苗免疫方式失敗原因之探討
頁籤選單縮合
題 名 | 基因工程產製豬白血球中介質Ⅱ對豬隻接種豬生殖與呼吸綜合症死毒免疫效力的影響=The Effect of Recombinant Porcine Interleukin-2 on the Immune Responses to Inactivated Porcine Reproductive and Respiratory Syndrome Virus in Swine |
---|---|
作 者 | 蕭世烜; 鄭謙仁; 張志成; 闕玲玲; 鄭益謙; 楊平政; 龐飛; | 書刊名 | 中華民國獸醫學會雜誌 |
卷 期 | 25:1 1999.03[民88.03] |
頁 次 | 頁23-33 |
分類號 | 437.657 |
關鍵詞 | 豬生殖與呼吸綜合症; 基因工程產製豬白血球中介質Ⅱ; 免疫力; 豬; Porcine reproductive and respiratory syndrome; Recombinant porcine interleukin-2; Vaccination; |
語 文 | 中文(Chinese) |
中文摘要 | 本研究的目的係探討基因工程產製之豬白血球中介質II(rpIL-2)對於已感染豬生 殖與呼吸綜合症(PRRS)的豬隻接種PRRS死毒免疫效力的影響。使用16頭PRRS抗體陽性豬隻, 分為4個實驗組,其中2組以間隔3週方式給予兩劑以氫氧化鋁膠吸附處理之PRRS(106 TCID50), 其中1組另含氫氧化鋁膠吸附處理之105U rpIL-2,這2組連同不予免疫的1組,均在第2次免 疫後3週進行鼻腔內接種104 TCID50之PRRS病毒,最後1組不免疫亦不攻毒作為環境對照組。 檢測項目包括免疫反應部份,含病毒中和抗體力價、周邊血液單核白血球毒殺病毒感染細胞的 能力、周邊血液淋巴球之增殖能力及肺泡巨噬細胞吞噬酵母菌以及產生超氧自由基和腫瘤壞 死因子的能力;臨床表徵部份,則含臨床症狀、平均日增重、死亡率及鼻腔分泌物的排毒量。 內含rpIL-2的死毒處理組,在第1次與第2次免疫後第3天之非特異性淋巴球增殖反應上及 第2次免疫後第14天之病毒特異性淋巴球增殖反應上有顯著提昇現象(P<0.05),且於臨床表 徵上與他組無明顯差異,然在病毒中和抗體力價、周邊血液單核白血球毒殺病毒感染細胞的能 力、攻毒後第21天肺泡巨噬細胞吞噬酵母菌及產生腫瘤壞死因子和超氧自由基的能力上則無 顯著提昇的效果。 |
英文摘要 | The objective of the study was to evaluate the effect of recombinant porcine interleukin-2 (rpIL-2) on the immune responses of porcine reproductive and respiratory syndrome virus (PRRSV) infected pigs immunized with inactivated PRRSV. Sixteen age-matched anti-PRRSV antibody positive pigs were randomly assigned to 4 groups. Two of the 4 groups received 2 doses of heat-inactivated PRRSV (106 TCID50) mixed with aluminum hydroxide within an interval of 3 weeks; 105U of rpIL-2 was also added to the heat-inactivated PRRSV preparation of 1 of the 2 groups. The 2 immunized groups and 1 unimmunized group were challenged intranasally with 104 TCID50 PRRSV 3 weeks after the 2nd immunization. The remaining group, neither immunized nor challenged, served as the environment control group. The immune responses, including virus neutralizing antibody titer, peripheral blood lymphocyte blastogenesis and peripheral blood mononuclear cell cytotoxicity against virus infected cells as well as phagocytosis of yeast, superoxide anion release, and tumor necrosis factor production by alveolar macrophages, as well as clinical observations, including symptoms, daily weight gain, mortality, and virus shedding, were examined and recorded. Upon comparsion, the group receiving heat-inactivated PRRSV and rpIL-2 showed significant (P<0.05) elevations on the non-specific lymphocyte blastogenesis on day 3 after the 1st and 2nd immunizations, and virus-specific lymphocyte blastogenesis on day 14 after the 2nd immunization without observable clinical alterations; however, there were no significant changes in virus neutralizing antibody titer, peripheral blood mononuclear cell cytotoxicity or phagocytosis of yeast, superoxide anion release, and tumor necrosis factor production by alveolar macrophages. |
本系統中英文摘要資訊取自各篇刊載內容。